RU2009147281A - Способы и композиции для диагностики и лечения волчанки - Google Patents

Способы и композиции для диагностики и лечения волчанки Download PDF

Info

Publication number
RU2009147281A
RU2009147281A RU2009147281/10A RU2009147281A RU2009147281A RU 2009147281 A RU2009147281 A RU 2009147281A RU 2009147281/10 A RU2009147281/10 A RU 2009147281/10A RU 2009147281 A RU2009147281 A RU 2009147281A RU 2009147281 A RU2009147281 A RU 2009147281A
Authority
RU
Russia
Prior art keywords
snp
tables
variation
figures
snps
Prior art date
Application number
RU2009147281/10A
Other languages
English (en)
Russian (ru)
Inventor
Тимоти В. БЕРЕНС (US)
Тимоти В. БЕРЕНС
Джеффри ХОМ (US)
Джеффри ХОМ
Уорд А. ОРТМАНН (US)
Уорд А. ОРТМАНН
Роберт Роял ГРЭХЕМ (US)
Роберт Роял ГРЭХЕМ
Original Assignee
Дженентек, Инк. (Us)
Дженентек, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Дженентек, Инк. (Us), Дженентек, Инк. filed Critical Дженентек, Инк. (Us)
Publication of RU2009147281A publication Critical patent/RU2009147281A/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/6858—Allele-specific amplification
    • G—PHYSICS
    • G06—COMPUTING OR CALCULATING; COUNTING
    • G06Q—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES, NOT OTHERWISE PROVIDED FOR
    • G06Q99/00—Subject matter not provided for in other groups of this subclass
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2533/00—Reactions characterised by the enzymatic reaction principle used
    • C12Q2533/10—Reactions characterised by the enzymatic reaction principle used the purpose being to increase the length of an oligonucleotide strand
    • C12Q2533/101—Primer extension
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/172—Haplotypes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
    • Y10T436/142222—Hetero-O [e.g., ascorbic acid, etc.]

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Physics & Mathematics (AREA)
  • General Business, Economics & Management (AREA)
  • Business, Economics & Management (AREA)
  • Theoretical Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Plant Pathology (AREA)
  • Transplantation (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
RU2009147281/10A 2007-05-21 2008-05-21 Способы и композиции для диагностики и лечения волчанки RU2009147281A (ru)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US93915607P 2007-05-21 2007-05-21
US60/939,156 2007-05-21
US1328307P 2007-12-12 2007-12-12
US61/013,283 2007-12-12

Publications (1)

Publication Number Publication Date
RU2009147281A true RU2009147281A (ru) 2011-06-27

Family

ID=40122294

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2009147281/10A RU2009147281A (ru) 2007-05-21 2008-05-21 Способы и композиции для диагностики и лечения волчанки

Country Status (14)

Country Link
US (1) US20110046094A1 (OSRAM)
EP (3) EP2612924B1 (OSRAM)
JP (4) JP5728226B2 (OSRAM)
KR (4) KR101729431B1 (OSRAM)
CN (3) CN104593488B (OSRAM)
AU (1) AU2008254582A1 (OSRAM)
BR (1) BRPI0811930B8 (OSRAM)
CA (1) CA2690608C (OSRAM)
ES (1) ES2661249T3 (OSRAM)
HK (1) HK1255086A1 (OSRAM)
IL (1) IL201949A0 (OSRAM)
MX (3) MX378733B (OSRAM)
RU (1) RU2009147281A (OSRAM)
WO (1) WO2008144761A2 (OSRAM)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2596391C2 (ru) * 2009-10-07 2016-09-10 Дженентек, Инк. Способ диагностики волчанки у человека

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101729431B1 (ko) * 2007-05-21 2017-04-21 제넨테크, 인크. 루푸스를 확인 및 치료하기 위한 방법 및 조성물
AU2009296393A1 (en) * 2008-09-26 2010-04-01 Genentech, Inc. Methods for treating, diagnosing, and monitoring lupus
US20100105061A1 (en) * 2008-10-29 2010-04-29 University Of Southern California Autoimmune genes identified in systemic lupus erythematosus (sle)
EP2403959A1 (en) * 2009-03-03 2012-01-11 Merck Serono S.A. Bank1 related snps and sle and/or ms susceptibility
BR112012022214A2 (pt) * 2010-03-01 2017-07-04 Alexion Pharma Inc métodos e composições para tratar doença de degos
EP2673372A4 (en) * 2011-02-10 2014-11-19 Genqual Corp PROCESS FOR PROGNOSIS AND ADMINISTRATION OF INFLAMMATORY DISEASES
US20130317006A1 (en) 2012-05-24 2013-11-28 Amy Yasko Use of polymorphisms for identifying individuals at risk of developing autism
WO2015081052A1 (en) 2013-11-27 2015-06-04 Yasko Amy Use of polymorphisms for identifying individuals at risk of developing autism
EP3822367A1 (en) * 2015-06-24 2021-05-19 Oxford BioDynamics PLC Detection processes using sites of chromosome interaction
CN110459312B (zh) * 2018-05-07 2024-01-12 深圳华大生命科学研究院 类风湿性关节炎易感位点及其应用
WO2021127589A1 (en) * 2019-12-18 2021-06-24 The Children's Hospital Of Philadelphia Novel druggable targets for the treatment of inflammatory diseases such as systemic lupus erythematosus (sle) and methods for diagnosis and treatment using the same
KR20240021336A (ko) 2022-08-09 2024-02-19 심재홍 수액 채취장치의 냉각기 구조
CN116030889A (zh) * 2023-02-16 2023-04-28 复旦大学 一种线粒体异质性分布中分配差异率计算的模型化方法

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4657760A (en) * 1979-03-20 1987-04-14 Ortho Pharmaceutical Corporation Methods and compositions using monoclonal antibody to human T cells
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4683203A (en) 1984-04-14 1987-07-28 Redco N.V. Immobilized enzymes, processes for preparing same, and use thereof
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US5206344A (en) 1985-06-26 1993-04-27 Cetus Oncology Corporation Interleukin-2 muteins and polymer conjugation thereof
IE61148B1 (en) 1988-03-10 1994-10-05 Ici Plc Method of detecting nucleotide sequences
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5225212A (en) * 1989-10-20 1993-07-06 Liposome Technology, Inc. Microreservoir liposome composition and method
ATE139258T1 (de) 1990-01-12 1996-06-15 Cell Genesys Inc Erzeugung xenogener antikörper
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) * 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5545806A (en) * 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
AU8507191A (en) 1990-08-29 1992-03-30 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
US5474796A (en) * 1991-09-04 1995-12-12 Protogene Laboratories, Inc. Method and apparatus for conducting an array of chemical reactions on a support surface
EP0822830B1 (en) 1995-04-27 2008-04-02 Amgen Fremont Inc. Human anti-IL-8 antibodies, derived from immunized xenomice
EP0823941A4 (en) 1995-04-28 2001-09-19 Abgenix Inc HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES
WO1997045559A1 (en) 1996-05-29 1997-12-04 Cornell Research Foundation, Inc. Detection of nucleic acid sequence differences using coupled ligase detection and polymerase chain reactions
EP1500329B1 (en) 1996-12-03 2012-03-21 Amgen Fremont Inc. Human antibodies that specifically bind human TNF alpha
EP1313880A2 (en) 2000-05-30 2003-05-28 PE Corporation (NY) Methods for detecting target nucleic acids using coupled ligation and amplification
US6900016B1 (en) * 2000-09-08 2005-05-31 Applera Corporation Polymorphisms in known genes associated with inflammatory autoimmune disease, methods of detection and uses thereof
EP1334113A4 (en) * 2000-10-20 2007-08-08 Expression Diagnostics Inc EVALUATION OF LEUCOCYTAIRE EXPRESSION LEVEL
US7205106B1 (en) 2001-07-20 2007-04-17 Roche Molecular Systems, Inc. Association of polymorphisms in IL4-related genes with autoimmune disease
JP2003061677A (ja) * 2001-08-28 2003-03-04 Olympus Optical Co Ltd 全身性エリテマトーデスの感受性遺伝子およびその使用
US20030119004A1 (en) 2001-12-05 2003-06-26 Wenz H. Michael Methods for quantitating nucleic acids using coupled ligation and amplification
US7022476B2 (en) * 2002-02-26 2006-04-04 New York Society For Ruptured And Crippled Maintaining The Hospital For Special Surgery Human FcγRIIB gene polymorphisms for assessing development of systemic lupus erythematosus and compositions for use thereof
CA2477611A1 (en) * 2002-03-01 2003-09-12 Ravgen, Inc. Rapid analysis of variations in a genome
WO2004083403A2 (en) 2003-03-18 2004-09-30 Applera Corporation Genetic polymorphisms associated with rheumatoid arthritis, methods of detection and uses thereof
WO2005086872A2 (en) * 2004-03-10 2005-09-22 Celera, An Applera Corporation Business Ptpn22 polymorphisms in diagnosis and therapy
EP1863927A2 (en) * 2005-03-15 2007-12-12 Ares Trading S.A. Compositions and methods for treating and diagnosing inflammatory disorders
PT2327792E (pt) 2005-08-05 2013-11-21 Genentech Inc Métodos e composições para a detecção de distúrbios autoimunes
US20070269827A1 (en) * 2006-05-18 2007-11-22 Oklahoma Medical Research Foundation Predicting and Diagnosing Patients With Autoimmune Disease
KR101729431B1 (ko) * 2007-05-21 2017-04-21 제넨테크, 인크. 루푸스를 확인 및 치료하기 위한 방법 및 조성물
AU2009296393A1 (en) * 2008-09-26 2010-04-01 Genentech, Inc. Methods for treating, diagnosing, and monitoring lupus

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2596391C2 (ru) * 2009-10-07 2016-09-10 Дженентек, Инк. Способ диагностики волчанки у человека
US10053734B2 (en) 2009-10-07 2018-08-21 Genentech, Inc. Methods for treating, diagnosing, and monitoring lupus

Also Published As

Publication number Publication date
WO2008144761A2 (en) 2008-11-27
CN104593488B (zh) 2018-06-12
KR20100021612A (ko) 2010-02-25
KR101729431B1 (ko) 2017-04-21
KR101651678B1 (ko) 2016-08-26
CN103298950A (zh) 2013-09-11
WO2008144761A3 (en) 2009-07-02
JP2010528590A (ja) 2010-08-26
US20110046094A1 (en) 2011-02-24
HK1189246A1 (en) 2014-05-30
HK1255086A1 (en) 2019-08-02
MX353428B (es) 2018-01-12
EP3318643A2 (en) 2018-05-09
ES2661249T3 (es) 2018-03-28
BRPI0811930B8 (pt) 2021-05-25
EP2158335A2 (en) 2010-03-03
CN103298950B (zh) 2015-01-21
JP2018126146A (ja) 2018-08-16
CN108753946A (zh) 2018-11-06
JP6080059B2 (ja) 2017-02-15
CN104593488A (zh) 2015-05-06
BRPI0811930B1 (pt) 2019-11-05
MX378733B (es) 2025-03-10
CA2690608A1 (en) 2008-11-27
IL201949A0 (en) 2010-06-16
MX2009012531A (es) 2009-12-03
EP2612924A3 (en) 2013-10-23
JP2017035088A (ja) 2017-02-16
KR101947093B1 (ko) 2019-02-12
EP3318643A3 (en) 2018-06-20
JP2015164426A (ja) 2015-09-17
KR20170042831A (ko) 2017-04-19
HK1209459A1 (en) 2016-04-01
EP2612924A2 (en) 2013-07-10
EP2612924B1 (en) 2017-12-20
AU2008254582A1 (en) 2008-11-27
KR20190015629A (ko) 2019-02-13
MX343167B (es) 2016-10-26
JP5728226B2 (ja) 2015-06-03
CA2690608C (en) 2020-07-21
KR20150133861A (ko) 2015-11-30
BRPI0811930A2 (pt) 2014-11-25

Similar Documents

Publication Publication Date Title
RU2009147281A (ru) Способы и композиции для диагностики и лечения волчанки
CA2881027C (en) Prognosis biomarkers in cartilage disorders
KR101545258B1 (ko) 운동 민감도 예측용 바이오마커
KR101992786B1 (ko) Cyp2e1 유전자의 메틸화 수준을 이용한 비만의 예측 또는 진단을 위한 정보제공방법 및 이를 위한 조성물
RU2012118596A (ru) Способы лечения, диагностики и мониторинга волчанки
AU2013301606A1 (en) Genetic markers for predicting responsiveness to FGF-18 compound
EP3873487A2 (en) A quantitative algorithm for endometriosis
EP2622101A2 (en) Genetic variations in the interleukin-6 receptor gene as predictors of the response of patients to treatment with interleukin-6 receptor inhibitors
CA2657493A1 (en) Prognostic method
KR101536213B1 (ko) 복부비만 예측용 ｓｎｐ 마커 및 이의 용도
JP5226256B2 (ja) 加齢黄斑変性症の発症リスクの予測方法
JP5721150B2 (ja) 加齢黄斑変性症の発症リスクの予測方法
JP5706612B2 (ja) 加齢黄斑変性症易罹患性の判定マーカー並びに判定方法及び判定キット
KR101532308B1 (ko) 복부비만 예측용 ｓｎｐ 마커 및 이의 용도
EP3315613B1 (en) Methods and kits for diagnosing or assessing the risk of cervical cancer
JP2007516719A (ja) 一塩基多型を含む二型糖尿病に関与するポリヌクレオチド、それを含むマイクロアレイ及び診断キット、並びにそれを利用したポリヌクレオチドの分析方法
CN103173454B (zh) 一种强迫性障碍相关基因GalR1的多态性位点及其应用
US10731219B1 (en) Method for preventing progression to metabolic syndrome
WO2012056694A1 (ja) 乳がん発症感受性の判定方法
CN105765077B (zh) 测定抗甲状腺药物诱导的粒细胞缺乏症风险的检测方法以及测定用试剂盒
KR20170142461A (ko) 치주질환 위험도 평가용 유전자 마커
KR101543774B1 (ko) 복부비만 예측용 ｓｎｐ 마커 및 이의 용도
EP4538391A1 (en) Method for obtaining useful data for the prediction of risk of fibrosis in a subject
EP2948567A1 (en) Methods and kits for treating and classifying individuals at risk of or suffering from a neurological dysfunction or disorder
CN103725781B (zh) 一种预测强直性脊柱炎易感性的试剂盒及方法